BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song P, Cai Y, Tang H, Li C, Huang J. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. Biosci Trends. 2017;11:389-398. [PMID: 28904327 DOI: 10.5582/bst.2017.01202] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Bi YH, Han WQ, Li RF, Wang YJ, Du ZS, Wang XJ, Jiang Y. Signal transducer and activator of transcription 3 promotes the Warburg effect possibly by inducing pyruvate kinase M2 phosphorylation in liver precancerous lesions. World J Gastroenterol 2019; 25(16): 1936-1949 [PMID: 31086462 DOI: 10.3748/wjg.v25.i16.1936] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Chen K, Zhu Y, Li X, Wang T. Clinical application of hepatectomy and thrombectomy for hepatocellular carcinoma with bile duct tumor thrombus. Asian Journal of Surgery 2022. [DOI: 10.1016/j.asjsur.2021.12.068] [Reference Citation Analysis]
3 Inchingolo R, Faletti R, Grazioli L, Tricarico E, Gatti M, Pecorelli A, Ippolito D. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol 2018; 10(7): 462-473 [PMID: 30079132 DOI: 10.4254/wjh.v10.i7.462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
4 Frión-Herrera Y, Gabbia D, Cuesta-Rubio O, De Martin S, Carrara M. Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells. Life Sci 2019;235:116817. [PMID: 31476309 DOI: 10.1016/j.lfs.2019.116817] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
5 Zhang Y, Wu W, Sun Q, Ye L, Zhou D, Wang W. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition. Mol Med Rep 2021;23:340. [PMID: 33760121 DOI: 10.3892/mmr.2021.11979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mohammed MM, Ramadan G, Zoheiry MK, El-Beih NM. Antihepatocarcinogenic activity of whey protein concentrate and lactoferrin in diethylnitrosamine-treated male albino mice. Environ Toxicol 2019;34:1025-33. [PMID: 31087429 DOI: 10.1002/tox.22773] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kamath A, Roudenko A, Hecht E, Sirlin C, Chernyak V, Fowler K, Mitchell DG. CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY) 2019;44:1306-22. [PMID: 30671612 DOI: 10.1007/s00261-018-1868-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
8 Zhang W, Qi S, Zhuo J, Wen S, Fang C. Concordance Study in Hepatectomy Recommendations Between Watson for Oncology and Clinical Practice for Patients with Hepatocellular Carcinoma in China. World J Surg 2020;44:1945-53. [PMID: 32020325 DOI: 10.1007/s00268-020-05401-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wang L, Wang FS. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges. Hepatol Int 2019;13:521-33. [PMID: 31352593 DOI: 10.1007/s12072-019-09967-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
10 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Front Cell Dev Biol 2021;9:669145. [PMID: 34422799 DOI: 10.3389/fcell.2021.669145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wörns MA, Galle PR. Patient prioritisation in HCC treatment: All (good) things come in threes. J Hepatol 2018;68:1311-2. [PMID: 29496352 DOI: 10.1016/j.jhep.2017.11.035] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
13 Chen W, Wei T, Chen Y, Yang L, Wu X. Downregulation of IRAK1 Prevents the Malignant Behavior of Hepatocellular Carcinoma Cells by Blocking Activation of the MAPKs/NLRP3/IL-1β Pathway. Onco Targets Ther 2020;13:12787-96. [PMID: 33363384 DOI: 10.2147/OTT.S260793] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Zhou T, Zhang W, Cheng D, Tang X, Feng J, Wu W. Preparation, Characterization, and in vivo Evaluation of NK4-Conjugated Hydroxycamptothecin-Loaded Liposomes. Int J Nanomedicine 2020;15:2277-86. [PMID: 32280220 DOI: 10.2147/IJN.S243746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Reference Citation Analysis]
16 Tang H, Song P, Wang Z, Han B, Meng X, Pan Y, Meng X, Duan W. A basic understanding of congenital extrahepatic portosystemic shunt: incidence, mechanism, complications, diagnosis, and treatment. Intractable Rare Dis Res 2020;9:64-70. [PMID: 32494552 DOI: 10.5582/irdr.2020.03005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Kong L, Wei G, Lv T, Jiang L, Yang J, Zhao Y, Yang J. Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma. Sci Rep 2021;11:696. [PMID: 33436856 DOI: 10.1038/s41598-020-80311-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Xu Q, Wang Y, Huang W. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Int Immunopharmacol 2021;92:107333. [PMID: 33486322 DOI: 10.1016/j.intimp.2020.107333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
19 Zhou ZF, Peng F, Li JY, Ye YB. Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. Onco Targets Ther 2019;12:7773-84. [PMID: 31571927 DOI: 10.2147/OTT.S222097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Wu Y, Wang PS, Wang BG, Xu L, Fang WX, Che XF, Qu XJ, Liu YP, Li Z. Genomewide identification of a novel six-LncRNA signature to improve prognosis prediction in resectable hepatocellular carcinoma. Cancer Med. 2018;7:6219-6233. [PMID: 30378276 DOI: 10.1002/cam4.1854] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
21 Bai H, Luo X, Liao D, Xiong W, Zeng M, Zheng B. Long Noncoding RNA PTTG3P Expression Is an Unfavorable Prognostic Marker for Patients With Hepatocellular Carcinoma. Technol Cancer Res Treat 2019;18:1533033819887981. [PMID: 31829099 DOI: 10.1177/1533033819887981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Lu WP, Tang HW, Yang ZY, Jiang K, Chen YL, Lu SC. A proposed modification for the Barcelona Clinic Liver Cancer staging system: Adding bile duct tumor thrombus status in patients with hepatocellular carcinoma. Am J Surg 2020;220:965-71. [PMID: 32336518 DOI: 10.1016/j.amjsurg.2020.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Usta S, Kayaalp C. Tumor Diameter for Hepatocellular Carcinoma: Why Should Size Matter? J Gastrointest Cancer 2020;51:1114-7. [PMID: 32851543 DOI: 10.1007/s12029-020-00483-z] [Reference Citation Analysis]
24 Yoshida M, Ogino H, Iwata H, Hattori Y, Hashimoto S, Nakajima K, Sasaki S, Hara M, Sekido Y, Mizoe JE, Shibamoto Y. Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. Oncol Lett 2019;17:3026-34. [PMID: 30854081 DOI: 10.3892/ol.2019.9922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Millet JD, Kamaya A, Choi HH, Dahiya N, Murphy PM, Naveed MZ, O’boyle M, Parra LA, Perez MG, Pirmoazen AM, Rodgers SK, Wasnik AP, Maturen KE. ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year. Journal of the American College of Radiology 2019;16:1656-62. [DOI: 10.1016/j.jacr.2019.05.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
26 Yang Y, He P, Li N. The Antitumor Potential of Extract of the Oak Bracket Medicinal Mushroom Inonotus baumii in SMMC-7721 Tumor Cells. Evid Based Complement Alternat Med 2019;2019:1242784. [PMID: 31662769 DOI: 10.1155/2019/1242784] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
27 Yao X, Zhao CR, Yin H, Wang K, Gao JJ. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. Acta Pharmacol Sin 2020;41:1609-20. [PMID: 32300243 DOI: 10.1038/s41401-020-0395-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
28 Zhang H, Xiong F, Qian K, Liu Y, Liang B, Xiong B, Yang F, Zheng C. Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma. Cancer Manag Res 2019;11:981-96. [PMID: 30774426 DOI: 10.2147/CMAR.S189208] [Reference Citation Analysis]
29 Yu MC, Lee CW, Lin CH, Wu CH, Lee YS, Tsai CL, Tsai CN. Differential hypermethylation of the VTRNA2-1 promoter in hepatocellular carcinoma as a prognostic factor: Tumor marker prognostic study. Int J Surg 2020;79:282-9. [PMID: 32417463 DOI: 10.1016/j.ijsu.2020.05.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
30 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
31 Hao W, Binbin J, Wei Y, Kun Y. Can Radiofrequency Ablation Replace Liver Resection for Solitary Colorectal Liver Metastasis? A Systemic Review and Meta-Analysis. Front Oncol 2020;10:561669. [PMID: 33312946 DOI: 10.3389/fonc.2020.561669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wei Y, Ye Z, Yuan Y, Huang Z, Wei X, Zhang T, Wan S, Tang H, He X, Song B. A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma. Liver Cancer 2020;9:414-25. [PMID: 32999868 DOI: 10.1159/000505696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Zhao XF, Li N, Lin DD, Sun LB. Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. Biomed Res Int. 2020;2020:5353695. [PMID: 32309434 DOI: 10.1155/2020/5353695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
34 Sochat MM, Piao J, Poddar N. Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report. J Gastrointest Cancer 2019;50:978-82. [PMID: 30105522 DOI: 10.1007/s12029-018-0159-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Li F, Bai L, Li S, Chen Y, Xue X, Yu Z. Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. J Cell Biochem 2020. [PMID: 32348599 DOI: 10.1002/jcb.29608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]